miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting <i>ADAM9</i> and <i>TGFBR2</i>.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28209612.
- Also identified by DOI 10.1158/0008-5472.CAN-16-2609.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Reversing epithelial-to-mesenchymal transition (EMT) in cancer cells has been widely considered as an approach to combat cancer progression and therapeutic resistance, but a limited number of broadly comprehensive investigations of miRNAs involved in this process have been conducted. In this study, we screened a library of 1120 miRNA for their ability to transcriptionally activate the E-cadherin gene <i>CDH1</i> in a promoter reporter assay as a measure of EMT reversal. By this approach, we defined miR-520f as a novel EMT-reversing miRNA. miR-520f expression was sufficient to restore endogenous levels of E-cadherin in cancer cell lines exhibiting strong or intermediate mesenchymal phenotypes. In parallel, miR-520f inhibited invasive behavior in multiple cancer cell systems and reduced metastasis in an experimental mouse model of lung metastasis. Mechanistically, miR-520f inhibited tumor cell invasion by directly targeting <i>ADAM9</i>, the TGFβ receptor <i>TGFBR2</i> and the EMT inducers <i>ZEB1, ZEB2</i>, and the snail transcriptional repressor <i>SNAI2</i>, each crucial factors in mediating EMT. Collectively, our results show that miR-520f exerts anti-invasive and antimetastatic effects <i>in vitro</i> and <i>in vivo</i>, warranting further study in clinical settings. <i>Cancer Res; 77(8); 2008-17. ©2017 AACR</i>.
Medical subject headings
- ADAM Proteins
- Epithelial-Mesenchymal Transition
- Membrane Proteins
- MicroRNAs
- Pancreatic Neoplasms
- Protein Serine-Threonine Kinases
- Receptors, Transforming Growth Factor beta
- Urinary Bladder Neoplasms